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A B S T R A C TObjective: Patient-reported outcomes are seldom validated measures
in clinical trials of acute respiratory tract infections (ARTIs) in primary
care. We developed and validated a patient-reported outcome
sum-scaling measure to assess the severity and functional impa-
cts of ARTIs. Methods: Qualitative interviews and ﬁeld testing
among adults with an ARTI were conducted to ascertain a high
degree of face and content validity of the questionnaire. Subse-
quently, a draft version of the Acute Respiratory Tract Infection
Questionnaire (ARTIQ) was statistically validated by using the partial
credit Rasch model to test dimensionality, objectivity, and reliability
of items. Test of known groups’ validity was conducted by comparing
participants with and without an ARTI. Results: The ﬁnal version of
the ARTIQ consisted of 38 items covering ﬁve dimensions (Physical-
upper, Physical-lower, Psychological, Sleep, and Medicine) and ﬁvesee front matter Copyright & 2013, International S
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14 CPH, Denmark.single items. All ﬁnal dimensions were conﬁrmed to ﬁt the Rasch model,
thus enabling sum-scaling of responses. The ARTIQ scores in partic-
ipants with an ARTI were signiﬁcantly higher than in those without
ARTI (known groups’ validity). Conclusion: A self-administered, multi-
dimensional, sum-scaling questionnaire with high face and content
validity and adequate psychometric properties for assessing severity
and functional impacts from ARTIs in adults is available to clinical trials
and audits in primary care.
Keywords: acute respiratory tract infections, patient-reported
outcome, questionnaire, Rasch analysis.
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Acute respiratory tract infections (ARTIs), which are often divided
into upper– and lower–respiratory tract infections, are among the
most frequent diseases seen by general practitioners (GPs) [1,2].
The substantial symptomatic and functional impairment caused
by these infections constitutes a major public health problem [2].
Symptoms in ARTIs are diverse and often contain elements
from the entire respiratory tract. Even individuals infected with the
same viral strain display a striking variance in symptoms and the
presentation is linked to illness duration [3]. Patient symptoms and
clinical signs are often not sensitive enough to discriminate
between the different types of ARTIs (such as acute bronchitis from
pneumonia). Because of this diagnostic uncertainty, diagnoses in
primary care may not always reﬂect the explicit pathophysiological
criteria commonly applied in medical science [4–6]. Hence, the
terms rhinitis, sinusitis, and bronchitis, among others, at bestindicate the anatomic site most affected at the time of consultation.
Accordingly, in a primary care setting, a precise diagnosis is often
not possible and symptom-based criteria (e.g., acute cough) are now
frequently used as inclusion criteria in pragmatic clinical trials [7,8].
In clinical conditions with no accepted “gold standard,” the
assessment of new treatment and diagnostic modalities may be
better addressed by using a patient-oriented approach [6,9],
bypassing the medically deﬁned “gold standard.”When assessing
treatment effects, cost, and so on of ARTIs in a primary care
setting, the vast majority of patients will recover uneventfully
with no or few hard end points such as mortality, highlighting
the need to measure the direct impact of disease on a patient’s
daily life. Furthermore, a change in a medical parameter, such as
auscultatory abnormalities or the normalization of a C-reactive
protein value, may only modestly reﬂect the patient’s own
experience of the illness and does not encompass any associated
symptoms (e.g., a cough that impacts daily activities or sleep) orociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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ence different effects on health status despite equal physiological
limitations) [10]. This is in line with the recognition that patient-
reported outcomes (PROs) are a key component in evaluating
health outcomes [11–14].
Several PRO measures have been developed to assess disease-
speciﬁc conditions such as asthma, pneumonia, chronic obstructive
pulmonary disease, and the common cold [15–18] and are valuable
in controlled trials with access to further diagnostic workup to
ensure certainty in the diagnosis. The instruments available, how-
ever, use a single sum score of all parameters: a global score. It can
be argued that when assessing different aspects of a disease as
experienced by a patient, that is, a biopsychosocial model, the name
itself indicates a number of different components that are not
directly comparable. Accordingly, a multidimensional approach with
several scales may be more suitable. To our knowledge, pragmatic
trials intended to reﬂect everyday routine in primary care treatment
of unspeciﬁc ARTIs do not have a qualitatively developed, psycho-
metrically validated sum-scaling instrument to measure sympto-
matic severity and functional impacts in ARTIs en bloc.
The aim of this study was to develop and validate a PRO
questionnaire with high face and content validity and adequate
psychometric properties to measure the severity and functional
impact of an ARTI in adults to determine the impact of the
infection itself and to evaluate the success or failure of thera-
peutic trials in primary care.Methods
The study was composed of 1) a literature and qualitative study
to ensure face and content validity of the PRO (phase 1 and 2,
respectively) and 2) a test of the PROs’ psychometric properties
(phase 3).
Phase 1: Item Generation
A list of all domains (physical, social, psychological, sleep, etc.) that
might be affected during an ARTI and their corresponding symp-
toms was generated by reviewing other questionnaires covering
speciﬁc ARTI diseases, looking at guidelines, and consulting col-
leagues. A ﬁrst draft version of the questionnaire was constructed.
Phase 2: Face and Content Validity
Interviews
The qualitative study aimed to expand our knowledge of the
symptomatic and functional impact of an ARTI. The participating
GPs identiﬁed patients who agreed to participate and scheduled
an interview no later than 48 hours after inclusion. The partic-
ipants were assigned to focus group or single interviews to
ensure adequate concept elicitation and cognitive assessment.
The goals of this phase were 1) to elicit participants’ experiences
with ARTIs for item generation and 2) to verify the comprehen-
siveness and patient understanding of the questionnaire. We
choose to conduct both single and focus group interviews to
secure different views and dynamics in generating input on the
questionnaire. All interviews took place at the Research Unit for
General Practice. No payment was given to interviewees.
Single interviews
The single interviews lasted approximately 30 minutes. The
purpose of these interviews was to understand which dimen-
sions of the subjects’ lives were affected and how this was
experienced. During the interview, the subject completed the
draft version of the questionnaire and was interviewed item by
item to ascertain relevance and comprehension.Focus group interviews
The group interviews lasted approximately 2 hours and were
audio-recorded. The focus group ﬁrst engaged in an open-ended
discussion about symptoms and functional impairments in an
ARTI. Then, the participants completed the draft version of the
questionnaire and discussed the instructions, item wording, and
ease of completion.
Timeline of qualitative study
We had a focus group session followed by single interviews. This
procedure was then repeated. The ﬁrst half of the qualitative
study was mainly on concept elicitation; the second part focused
more on cognitive assessment of the questionnaire, the corre-
sponding wording of items, and response categories.
Analysis of interviews (focus and single)
R.A. conducted all interviews. H.T. was a comoderator in the focus
groups. After each interview, R.A. and H.T. analyzed data and the
draft version of the questionnaire was changed according to relevant
input. The draft version of the questionnaire was successively used
in the next interviews until further interviews gave no additional
information, and the participants completed the questionnaire with-
out problems or misunderstandings of the wording or meaning [19].
Items were worded according to participants’ suggestions.
Phase 3: Psychometric Properties
Recruitment and participants
The psychometric properties of the ﬁnal version of the question-
naire were tested in subjects with and without an ARTI who
consulted their GP. Fifteen GPs were invited to enroll 20 subjects
with and 20 subjects without an ARTI (scheduled for consulta-
tions and without complaints of fever or ARTI symptoms). All
ARTI diagnoses were made solely on clinical grounds. Subjects




Many PROs consist of ordinal response categories measuring the
severity of the latent health trait (e.g., functional ability, pain, or
happiness) as perceived by the respondent. When summing raw
scores of items in a scale, however, an assumption of unidimen-
sionality is made, that is, that the items in the questionnaire
describe different aspects of the same construct (dimension),
allowing raw scores of the items to be added together [20,21].
Rasch models are tests for unidimensionality in the sense that
they investigate whether responses from persons can be listed
according to item difﬁculty, from lowest to highest, in a proba-
bilistic Guttmann pattern [22,23]. Items with poor ﬁt to a Rasch
model may be excluded in an iterative process, with one item
removed at a time and model ﬁt reestimated accordingly. When
items ﬁt a Rasch model, objective (invariant) measurement is
obtained. Moreover, Rasch models can also test whether one or
more items possess uniform or nonuniform differential item
functioning (DIF), indicating that an item has unequal function
in different subgroups, for example, sex, age, and diagnostic
groups, and thereby disturbs the invariant measurement [23].
They also estimate whether response categories function as
intended [24,25], that is, that an ordinal ranking of the response
categories is obtained.
The pairwise estimation procedure implemented in the soft-
ware program RUMM2030 was used to estimate item parameters
in the partial credit Rasch model for dichotomous and polytomous
items [26]. The overall ﬁt of the model and scales was assessed by
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ﬁt statistics were used to identify poorly ﬁtting items. To adjust
for multiple testing, the signiﬁcance level of the Wright-
Panchapakesan statistics was set to 0.01 when determining
unidimensionality. Reliability and capacity of the scale to differ-
entiate between patients were assessed by using Cronbach’s alpha
and the Person Separation Index, respectively [28].
Known groups’ validity
It provides credibility to construct validity when the PRO can
discriminate between a group of individuals known to have a
particular trait and a group of individuals who do not have
that trait.
Analyses are presented asmedian (interquartile range) and n (%)
as appropriate. Differences in subject characteristics and ARTIQ
scores of single items and ARTIQ sum-scores of dimensions
between the ARTI group and the noninfected control group (known
groups’ validity) were assessed by using a nonparametric Wilcoxon
signed-rank test. A P value of o0.05 was considered signiﬁcant.
The study was approved by the Danish Data Protection
Agency.Results
Phase 1: Item Generation
A ﬁrst draft of the questionnaire encompassed 48 items: 38 that
graded severity in four response categories and 10 dichoto-
mous items.
Phase 2: Face and Content Validity
Two focus group sessions (each with three participants) and 12
single interviews formed the basis of the qualitative study (Table 1).
Based on the information provided, 46 items were identiﬁed in six
domains: Physical (23 items), Psychological (5 items), Energy (3
items), Sleep (4 items), Medicine (9 items), and Social (2 items)
(Table 2). The domain Energy, as identiﬁed by participants, included
questions that in medical terms could be regarded as physical
symptoms, such as item 26 “Felt dizzy.” The lay word “dizzy” in this
context, however, should not be mistaken for the medical term
“vertigo,” but rather a vague description of feeling unwell. Response
categories in the ARTIQ were readjusted to a three-point scale
phrased as follows: No, Yes—some, and Yes—a lot. Ten dichotomized
items (“Yes”, “No”) (items 36–46) were maintained.
Phase 3: Psychometric Properties
Recruitment and participants
GPs each recruited 5 to 40 participants; 274 participants completed
the ﬁnal draft version of the questionnaire; 13 (5%) were excluded
because of missing data and 2 in accordance with exclusion
criteria (age o 18 years), leaving 259 participants (Table 1).Table 1 – Demographic data of participants.
Data collection No. ARTI þ
Cognitive interviews 12 12
Focus groups 6 6
Validation study 259 122
ARTI þ, acute respiratory tract infection according to treating general prRasch analysis
Four domains (Physical, Psychological, Sleep, and Medicine)
were subjected to Rasch modeling; the remaining two domains
(Energy and Social) were not considered because of the low
number of items.
Physical Items. A score summing all the 23 Physical domain
items did not ﬁt the Rasch model. Prespeciﬁed subgroup analysis
of the Physical domain identiﬁed two subdomains, namely,
Physical-Upper respiratory tract (PhysUP) and Physical-Lower
respiratory tract (PhysLOW) (Table 2). Of the 15 items covering
PhysUP, 13 items ﬁtted the Rasch model (Tables 2 and 3). Three
PhysUP items possessed uniform DIF in relation to participants
with and without an ARTI. Because of the different directions and
magnitude of the DIF in these three items, the DIF leveled out.
Among the two poorly ﬁtting items (item 15 “Muscle pains” and
item 16 “Joint pains”), the face validity was low for “Joint pains”
and hence this item was excluded (Tables 2 and 4). Item 15
“Muscle pains” was retained as a single item because of its high
content validity and its ability to discriminate between those with
and without an ARTI (Tables 2 and 4). The eight PhysLOW items
ﬁtted a unidimensional model, and none possessed DIF (Tables 2
and 3).
Sleep. All four items in this dimension ﬁtted the Rasch model,
and none possessed DIF (Tables 2 and 3).
Psychological. This ﬁve-item domain was unidimensional
(Tables 2 and 3). Item 28 “Not feeling yourself” possessed uniform
DIF relative to an ARTI. Nevertheless, the item was maintained
because of its content validity and reliability.
Medicine. The nine items did not initially exhibit unidimension-
ality. The poor ﬁt was due to item 37 “Taken painkillers.” Because
paracetamol, nonsteroidal anti-inﬂammatory drugs, and acetylsa-
licylic acid are over-the-counter drugs in Denmark, and because
these drugs have both analgesic and fever-reducing properties, it
may be difﬁcult to distinguish between item 36 “Taken medicine to
reduce fever” and item 37 “Taken painkillers.” Although the face
validity was high, item 37 was excluded because of this possible
ambiguity. The remaining eight items ﬁtted the Rasch model, and
no items possessed DIF (Tables 2 and 3).
No DIF was identiﬁed relative to gender in any of the 46 items.
In four PhysUP items (items 7, 14, 18, and 19) and item 11 in
PhysLOW, the response categories did not function as intended.
Items with inadequately functioning response categories were
rescored by collapsing the responses “Yes —some” with “Yes—a
lot.” After rescoring, the overall ﬁt of the PhysUP domain and the
PhysLOW domain to the Rasch model increased.
The overall ﬁt statistics of the ﬁve ARTIQ domains are
presented in Table 3, including adequate values of reliability: all
Wright-Panchapakesan statistics were insigniﬁcant; Chronbach’s
















1. Dry cough Physical 6.329 0.096665 0.096 Included PhysUP
2. Coughing up mucus Physical 3.953 0.266624 0.247 Included PhysUP
3. Painful pressure in ears Physical 4.059 0.255207 0.441 Included PhysUP
4. Blocked nose Physical 1.055 0.787859 0.107 Included PhysUP
5. Runny nose Physical 3.314 0.34575 0.03 Included PhysUP
6. Sneezing—no ARTI Physical 3.929 0.269277 0.606 Included PhysUP, DIF
6. Sneezing—ARTI þ Physical 2.008 0.57069 0.23 Included PhysUP, DIF
7. Watery eyes—no ARTI Physical 2.745 0.432674 0.456 Included PhysUP
7. Watery eyes—ARTI þ Physical 3.17 0.3662 0.737 Included PhysUP, DIF
8. Hoarseness Physical 7.975 0.046524 0.041 Included PhysUP
9. Feeling feverish Physical 6.156 0.104251 0.429 Included PhysLOW
10. Sweats Physical 2.038 0.564656 0.704 Included PhysLOW
11. Chills Physical 3.769 0.287563 0.183 Included PhysLOW
12. Headache Physical 9.684 0.021455 0.515 Included PhysUP
13. Tickles in the throat Physical 6.561 0.087294 0.473 Included PhysUP
14. Sore throat—no ARTI Physical 1.894 0.594612 0.583 Included PhysUP
14. Sore throat—ARTI þ Physical 0.762 0.858581 0.575 Included PhysUP, DIF
15. Muscle pains Physical 20.842 0.000115 0.104 Included single Item
16. Joint pains Physical 30.301 0.000001 0.021 Excluded
17. Chest pain Physical 2.885 0.409619 0.416 Included PhysLOW
18. Painful sinuses Physical 8.342 0.039458 0.727 Included PhysUP
19. Swollen glands Physical 7.298 0.06298 0.428 Included PhysUP
20. Loss of appetite Physical 0.632 0.889047 0.069 Included PhysLOW
21. Problems breathing Physical 10.75 0.01316 0.125 Included PhysLOW
22. Wheezing Physical 1.403 0.704885 0.219 Included PhysLOW
23. Shortness of breath Physical 4.221 0.23855 0.51 Included PhysLOW
24. Difﬁculty in thinking clearly? Psychological 3.505 0.320075 0.952 Included Psych
25. Difﬁculty in going about your
daily business
Psychological 2.581 0.460838 0.151 Included Psych
26. Felt dizzy Energy Excluded
27. Felt tired Energy Included single item
28. Not feeling yourself—no ARTI Psychological 1.884 0.59687 0.069 Included Psych, DIF
28. Not feeling yourself—ARTI þ Psychological 2.805 0.422647 1.053 Included Psych, DIF
29. Being so unwell you had to stay in
bed
Energy Included single item
30. Poor quality of sleep Sleep 5.064 0.167197 0.757 Included Sleep
31. Waking up several times at night Sleep 2.68 0.443613 1.019 Included Sleep
32. Difﬁculty falling asleep Sleep 10.015 0.018438 0.528 Included Sleep
33. Been awake most of the night Sleep 4.601 0.203426 1.248 Included Sleep
34. Been in a bad mood Psychological 2.844 0.416254 0.082 Included Psych
35. Been irritable Psychological 0.271 0.965458 0.1 Included Psych
36. Taken medicine against fever Medicine 17.152 0.000658 0.588 Included Medicine
37. Taken painkillers Medicine 6.162 0.045915 2.173 Excluded
38. Taken antibiotics (such as
penicillin)
Medicine 4.506 0.105078 0.134 Included Medicine
39. Taken asthma/COPD spray/
inhalator
Medicine 1.025 0.599084 1.436 Included Medicine
40. Taken asthma/COPD tablets Medicine 3.457 0.177543 0.748 Included Medicine
41. Taken antitussives Medicine 3.078 0.214545 1.387 Included Medicine
42. Taken eye drops Medicine 7.27 0.02638 0.903 Included Medicine
43. Taken nasal sprays Medicine 2.691 0.260466 1.224 Included Medicine
44. Taken herbal medicine Medicine 3.604 0.164932 0.089 Included Medicine
45. Signed in sick or cancelled work-
related activities
Social Included single item
46. Cancelled leisure activities Social Included single item
Notes. Items 15, 27, 29, 37, 45, and 46 exhibited high face validity. Items 16 and 26 had low face validity. Items 1 to 35 had three degrees of
freedom. Items 36 to 46 had two degrees of freedom.ARTI þ, acute respiratory tract infection according to treating general practitioner; ARTIQ,
Acute Respiratory Tract Infection Questionnaire; COPD, chronic obstructive pulmonary disease; DIF, differential item functioning; Phys,
Physical; PhysLOW, Physical-Lower respiratory tract; PhysUP, Physical-Upper respiratory tract.
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Table 3 – Wright-Panchapekesan (WP) ﬁt statistics, Person separation index (PSI), and Cronbach’s alpha of the
ﬁve dimensions in the ARTIQ.
Dimensions (no. of items) WP Degrees of freedom P PSI Cronbach’s alpha
Physical—upper airways (13) 73.08 48 0.01 0.75 0.85
Physical—lower airways (8) 31.85 24 0.13 0.51 0.83
Psychological (5) 13.89 18 0.74 0.47 0.84
Sleep (4) 22.36 12 0.03 0.72 0.89
Medicine (8) 31.79 16 0.01 0.68 0.53
ARTIQ, Acute Respiratory Tract Infection Questionnaire.
 Signiﬁcance level at 0.01 to adjust for multiple testing.
Table 4 – ARTIQ scores of domains and single items of participants with and without ARTI.
Healthy Ill
(n ¼ 137) (n ¼ 122)
Range
Median IQR Max–Min Median IQR Max–Min
P
Rasch model domains (no. of items)
Physical—upper airways (13) 0–26 2 0–3 0–16 10 7–14 0–19 o0.001
Physical—lower airways (8) 0–16 0 0–1 0–5 6 3–8 0–13 o0.001
Psychological (5) 0–10 0 0–1 0–10 3 2–5 0–9 o0.001
Sleep (4) 0–8 1 0–3 0–8 3 2–7 0–8 o0.001
Medicine (8) 0–8 0 0–0 0–5 1 0–2 0–5 o0.001
Separate items
Muscle pain (item 15) 0–2 0 0–1 0–2 1 0–1 0–2 o0.001
Joint pains (item 16) 0–2 0 0–1 0–2 0 0–1 0–2 0.127
Felt dizzy (item 26) 0–2 0 0–0 0–2 0 0–1 0–2 0.088
Felt tired (item 27) 0–2 1 0–1 0–2 2 1–2 0–2 o0.001
Being so unwell … (item 29) 0–2 0 0–0 0–1 1 0–1 0–2 o0,001
Signed in sick or … (item 45) 0–1 0 0–0 0–1 1 0–1 0–1 o0.001
Cancelled leisure activities (item 46) 0–1 0 0–0 0–1 1 0–1 0–1 o0.001
ARTI, acute respiratory tract infection; IQR, interquartile range.
 P value from a Wilcoxon signed-rank test.
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example of the questionnaire layout is presented in Figure 1.Discriminative ability/known groups’ validity
Based on the item scores No ¼ 0, Yes—some ¼ 1, and Yes—a lot ¼ 2
for polytomous items and the item scores No ¼ 0 and Yes ¼ 1 for
dichotomous items, the scores from participants with and with-
out an ARTI were analyzed in single items as well as sum-scores
of validated domains. All scales and single items (except item 16
“Joint pains” and item 26 “Felt dizzy”) exhibited signiﬁcantly
higher scores in participants with an ARTI (Table 4).Discussion
Respiratory tract infections are common in primary care, and
because no gold standard exists, the need for sound measure-
ments of PROs on severity and functional impact is essential. TheFig. 1 – An example of the layout of items and response categoARTIQ has been developed to meet this need. The ARTIQ uses
both qualitative and quantitative psychometrical methods to
ensure high face and content validity and unidimensional invar-
iant measurement with reliable sum-scores for the ﬁve scales:
PhysUP and PhysLOW symptoms, Psychological, Sleep, and Med-
icine, plus ﬁve single items (Table 2).
Strengths and Limitations of the Study
In PROs, great care must be exercised to ensure an adequate and
understandable description of the patient’s condition [10,14],
particularly when no gold standard exists. The qualitative part
of the present study, involving future users in the development of
questionnaire items, wording, and response categories, ensured a
high level of face and content validity of the broad term “severity
and functional impact” or “bothersomeness” of an ARTI, and
ascertained the acceptability of the questionnaire (proportion of
missing data o5%). The recall period was set to 24 hours to
ascertain that the symptom or impairment measured wasries in the Acute Respiratory Tract Infection Questionnaire.
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participant at testing but still sensitive to a change in severity
of the ARTI in question. Barret et al. [15] used the same recall
time in the WURSS questionnaire of the common cold.
The ability of the ARTIQ dimensions to discriminate between
participants with and without an ARTI on the basis of sum-
scoring of the scales is not of diagnostic use. Nevertheless, if
applied in trials testing the participants at different time points, it
illustrates the anticipated response to change in a recovery from
an ARTI to a normal level and thus determines when subjects can
be regarded as cured. We believe that the term sensitivity to
change or responsiveness is difﬁcult to assess in an acute
respiratory condition with no gold standard or similar question-
naires for comparison because deciding which time points to
compare is complex: is the disease gradually or acutely worsen-
ing or is the patient recovering?
It is important to acknowledge that the DIF of the psycho-
logical dimension must be taken into account when sum-scoring
a longitudinal cohort study. In a randomized controlled trial,
however, the DIF will not affect the results because of randomi-
zation.
The broad inclusion criteria (any ARTI) without application of
strict diagnostic measures may raise doubts about the speciﬁcity
of the illnesses included. Realistic and pragmatic research, how-
ever, will beneﬁt from an instrument that is comprehensive and
symptom based and covers the full range of illnesses met in
primary care. Nevertheless, the current ﬁndings should be exter-
nally validated in a different ARTI population to better assess the
generalizability of the ﬁndings.
Findings in Relation to Other Studies
Unpublished questionnaires and diaries have been used to
measure PRO in clinical trials despite the lack of rigorous
validation of the applied instrument(s); this is not appropriate
[14]. Often, the questionnaires were developed without qualita-
tive methods ensuring relevance and comprehensibility. An
example to follow could be the disease-speciﬁc WURSS question-
naire on the common cold, which has been developed and
standardized as a result of the work by Barret et al. [15]. The
ARTIQ, however, is the ﬁrst validated PRO questionnaire devel-
oped to measure the functional impairment in an ARTI en bloc,
which in selected studies may better reﬂect the diagnostic
uncertainties of primary care research in a pragmatic trial.
Furthermore, the ARTIQ is the ﬁrst Rasch-tested ARTI question-
naire. It comprises ﬁve independent scales for comparing each
dimension affected because we believe that adding different
scales into one single questionnaire sum score cannot be justi-
ﬁed; in addition, discriminative power will diminish. The number
of items (43) is comparable to other research questionnaires
[15,18] as is time of completion (5 minutes).
Unanswered Questions and Future Research
The ARTIQ was developed in Danish. Any new language version
of the questionnaire must also be tested by using Rasch analysis
to ensure its measurement properties. Rasch analysis enables
invariant comparison across subjects of different nationalities
and cultural or ethnic backgrounds. The ARTIQ will be made
freely available for nonproﬁt research.Acknowledgments
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